Welcome to our dedicated page for Prelude Therapeutics SEC filings (Ticker: PRLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company. Through these regulatory documents, investors can review how Prelude describes its business, pipeline, risks, and financial condition as it advances programs such as SMARCA2 and KAT6A degraders, mutant selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms, and mutant CALR-targeted degrader antibody conjugates (DACs).
Key filings include annual reports on Form 10-K, which provide an overview of Prelude’s precision oncology strategy, target selection, collaborations, and risk factors, and quarterly reports on Form 10-Q, which update on operating expenses, cash runway, and development progress. Current reports on Form 8-K disclose material events such as the exclusive option agreement with Incyte for the JAK2V617F program, expanded arrangements with AbCellera Biologics, clinical portfolio reprioritizations, Nasdaq listing compliance updates, and changes in board or executive roles.
Investors interested in ownership and governance can also use SEC filings to track equity financings, non-voting common stock issuances, and other capital structure changes described in transaction-related 8-Ks and registration statements. These documents outline terms of option agreements, securities purchase agreements, and related registration rights for Prelude’s stock.
On Stock Titan, each new PRLD filing is captured from EDGAR and paired with AI-powered summaries that highlight the most relevant points, such as pipeline focus, collaboration economics, cash position commentary, and listing status updates. This helps readers navigate lengthy reports and quickly locate information on topics like JAK2V617F program economics, SMARCA2 and KAT6A development plans, and the impact of strategic decisions on Prelude’s financial profile.
Use this page to access Prelude Therapeutics’ 10-K, 10-Q, 8-K and related filings, along with concise AI explanations that clarify technical disclosures and regulatory language for PRLD stock watchers.
OrbiMed-affiliated funds filed Amendment No. 3 to their Schedule 13D on Prelude Therapeutics to update ownership after a recent underwritten offering.
Prelude sold 18,018,014 shares at $4.44 and pre-funded warrants for 2,252,252 shares at $4.4399, bringing total outstanding shares to 80,971,642. OrbiMed’s vehicles now beneficially own 12,935,071 shares of common stock, representing about 16% of the company. This includes 11,808,945 shares held by OrbiMed Private Investments VI and 1,126,126 shares held by OrbiMed Genesis Master Fund. Certain OrbiMed funds also hold non-voting shares that can only convert into voting shares if doing so would keep their ownership below a 9.99% blocker threshold.
Prelude Therapeutics Inc reported that investment entities affiliated with OrbiMed made indirect open-market purchases of its Common Stock in connection with an underwritten public offering. OrbiMed-related funds acquired blocks of 1,126,126 and 1,689,189 shares at $4.44 per share, with indirect holdings after one transaction reaching 11,808,945 shares. The securities are held of record by OrbiMed-managed funds, and OrbiMed Advisors exercises voting and investment power through a management committee. David P. Bonita, a director and ten percent owner, reports these positions but, together with the OrbiMed entities, disclaims beneficial ownership except to the extent of any pecuniary interest.
Prelude Therapeutics Inc reported that investment entities affiliated with OrbiMed made significant open-market purchases of its common stock. OrbiMed-related funds bought a combined 2,815,315 shares at $4.44 per share in an underwritten public offering, with all holdings reported as indirect and subject to detailed ownership footnotes.
The filing attributes shares to OrbiMed Private Investments VI, OrbiMed Partners Master Fund, and OrbiMed Genesis Master Fund through their respective general partners and advisors, while OrbiMed reporting entities and individual managers disclaim beneficial ownership beyond any pecuniary interest. One OrbiMed representative, David Bonita, serves on Prelude’s board.
Baker Bros. Advisors filed an amended Schedule 13D reporting beneficial ownership of 10,295,301 shares of Prelude Therapeutics common stock, representing 15.5% of the class. This reflects participation in an April 2026 offering of 18,018,014 common shares and prefunded warrants to purchase 2,252,252 shares at $4.4399 each, alongside a $4.44 common share price.
The filing explains that these prefunded warrants and separate non-voting common stock are subject to ownership caps of 4.99% and 9.99%, adjustable up to 19.99% with 61 days’ notice. It also describes option grants to Baker-affiliated directors, an omnibus option amendment tying exercisability to a current adviser representative, and a director lock-up running from April 20 to June 19, 2026.
Prelude Therapeutics Inc reported that investment funds advised by Baker Bros. Advisors LP made open-market purchases of prefunded warrants in an underwritten public offering. 667, L.P. acquired 114,601 prefunded warrants and Baker Brothers Life Sciences LP acquired 2,137,651 prefunded warrants, each at $4.4399 per warrant.
The prefunded warrants are exercisable into common stock on a 1-for-1 basis at an exercise price of $0.0001 per share, with no expiration date. Exercises are limited so that the holders and certain affiliates do not exceed 4.99% beneficial ownership, a cap the funds can adjust up to 19.99% with advance written notice. Baker Bros. Advisors LP has investment and voting discretion over the funds’ positions, while various Baker entities and Julian and Felix Baker disclaim beneficial ownership beyond their pecuniary interests.
Prelude Therapeutics Incorporated has priced an underwritten equity offering to raise capital for its oncology pipeline and operations. The company agreed to sell 18,018,014 shares of common stock at $4.44 per share and pre-funded warrants to purchase up to 2,252,252 shares at $4.4399 per warrant with a $0.0001 exercise price. Gross proceeds are expected to be about $90.0 million, with estimated net proceeds of approximately $85.5 million after fees and expenses. Prelude plans to use the funds mainly for general corporate purposes, including research, preclinical and clinical development, working capital, and capital expenditures, and currently expects its cash plus these proceeds to fund operations into the second quarter of 2028.
Prelude Therapeutics Incorporated has priced an underwritten equity offering to raise capital for its oncology pipeline and operations. The company agreed to sell 18,018,014 shares of common stock at $4.44 per share and pre-funded warrants to purchase up to 2,252,252 shares at $4.4399 per warrant with a $0.0001 exercise price. Gross proceeds are expected to be about $90.0 million, with estimated net proceeds of approximately $85.5 million after fees and expenses. Prelude plans to use the funds mainly for general corporate purposes, including research, preclinical and clinical development, working capital, and capital expenditures, and currently expects its cash plus these proceeds to fund operations into the second quarter of 2028.
Prelude Therapeutics (PRLD) is offering 18,018,014 shares of common stock and, in lieu of shares to certain investors, 2,252,252 pre‑funded warrants exercisable into one share each. The public offering price is $4.44 per share (pre‑funded warrant price $4.4399). Net proceeds are estimated at approximately $85.5 million, which the company expects to fund operations into the second quarter of 2028 based on preliminary estimates. Certain investment entities affiliated with directors will purchase an aggregate of 2,815,315 shares and 2,252,252 pre‑funded warrants at the public offering price. The pre‑funded warrants have an exercise price of $0.0001, contain a 4.99% beneficial ownership limitation (adjustable to 19.99% with notice), and will not be listed for trading.
Prelude Therapeutics (PRLD) is offering 18,018,014 shares of common stock and, in lieu of shares to certain investors, 2,252,252 pre‑funded warrants exercisable into one share each. The public offering price is $4.44 per share (pre‑funded warrant price $4.4399). Net proceeds are estimated at approximately $85.5 million, which the company expects to fund operations into the second quarter of 2028 based on preliminary estimates. Certain investment entities affiliated with directors will purchase an aggregate of 2,815,315 shares and 2,252,252 pre‑funded warrants at the public offering price. The pre‑funded warrants have an exercise price of $0.0001, contain a 4.99% beneficial ownership limitation (adjustable to 19.99% with notice), and will not be listed for trading.
Prelude Therapeutics Incorporated furnished an update on its precision oncology pipeline and cash position, highlighted by new preclinical data for lead candidate PRT13722, a first-in-class, orally bioavailable, highly selective KAT6A degrader for HR+/HER2- breast cancer.
At the AACR Annual Meeting 2026, PRT13722 showed potent preclinical antitumor activity, including complete responses in multiple breast cancer models, and signs of a more favorable hematologic safety profile than dual KAT6A/B inhibitors. An IND filing for PRT13722 is planned for mid‑2026, with a Phase 1 trial expected to begin in the second half of 2026.
The company also highlighted PRT12396, a JAK2V617F‑mutant selective JH2 inhibitor now in Phase 1 for myeloproliferative neoplasms, and an early mCALR‑targeted degrader antibody conjugate program. Prelude reported $106 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025, which it expects to fund operations into the second quarter of 2027.
Prelude Therapeutics Incorporated furnished an update on its precision oncology pipeline and cash position, highlighted by new preclinical data for lead candidate PRT13722, a first-in-class, orally bioavailable, highly selective KAT6A degrader for HR+/HER2- breast cancer.
At the AACR Annual Meeting 2026, PRT13722 showed potent preclinical antitumor activity, including complete responses in multiple breast cancer models, and signs of a more favorable hematologic safety profile than dual KAT6A/B inhibitors. An IND filing for PRT13722 is planned for mid‑2026, with a Phase 1 trial expected to begin in the second half of 2026.
The company also highlighted PRT12396, a JAK2V617F‑mutant selective JH2 inhibitor now in Phase 1 for myeloproliferative neoplasms, and an early mCALR‑targeted degrader antibody conjugate program. Prelude reported $106 million in cash, cash equivalents, restricted cash and marketable securities as of December 31, 2025, which it expects to fund operations into the second quarter of 2027.
Prelude Therapeutics Inc filed an initial Form 3 for Chief Medical Officer Charles Q. Morris. This filing identifies him as an officer and subject to insider reporting rules but, in this excerpt, shows no reported transactions or holdings data.
Prelude Therapeutics Incorporated appointed Dr. Charles Morris as Executive Vice President and Chief Medical Officer, effective April 20, 2026. He brings over 30 years of oncology drug development experience, including prior CMO roles at Lava Therapeutics, Celyad Oncology, Radius Health, ImmunoGen and Allos Therapeutics.
Under his employment agreement, Dr. Morris will receive a $535,000 initial annual base salary, a discretionary target bonus up to 40% of base salary, and an option to purchase 450,000 shares of common stock vesting over four years. If his employment is terminated without Cause or he resigns for Good Reason, he is eligible for nine months of salary and healthcare premiums, increasing to 12 months of salary and healthcare, 100% of his target bonus, and full vesting of equity awards if such termination occurs within 12 months after a Change in Control.
The company describes itself as a clinical-stage precision oncology firm with programs in KAT6A degraders and JAK2V617F mutant-selective inhibitors, aiming to move two lead programs into clinical development in 2026.